Cite
A selective CB2R agonist (JWH133) protects against pulmonary fibrosis through inhibiting FAK/ERK/S100A4 signaling pathways
MLA
Xiao Wu, et al. “A Selective CB2R Agonist (JWH133) Protects against Pulmonary Fibrosis through Inhibiting FAK/ERK/S100A4 Signaling Pathways.” BMC Pulmonary Medicine, vol. 23, no. 1, Nov. 2023, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s12890-023-02747-3.
APA
Xiao Wu, Lina Chen, Yiju Cheng, Yuquan Zhang, Wenting Yang, Lin Pan, Chenkun Fu, Honglan Zhu, & Menglin Zhang. (2023). A selective CB2R agonist (JWH133) protects against pulmonary fibrosis through inhibiting FAK/ERK/S100A4 signaling pathways. BMC Pulmonary Medicine, 23(1), 1–9. https://doi.org/10.1186/s12890-023-02747-3
Chicago
Xiao Wu, Lina Chen, Yiju Cheng, Yuquan Zhang, Wenting Yang, Lin Pan, Chenkun Fu, Honglan Zhu, and Menglin Zhang. 2023. “A Selective CB2R Agonist (JWH133) Protects against Pulmonary Fibrosis through Inhibiting FAK/ERK/S100A4 Signaling Pathways.” BMC Pulmonary Medicine 23 (1): 1–9. doi:10.1186/s12890-023-02747-3.